Literature DB >> 24997150

Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.

Yoshihiro Inamoto1, Paul J Martin2, Barry E Storer2, Jeanne Palmer3, Daniel J Weisdorf4, Joseph Pidala5, Mary E D Flowers2, Mukta Arora4, Madan Jagasia6, Sally Arai7, Xiaoyu Chai2, Steven Z Pavletic8, Georgia B Vogelsang9, Stephanie J Lee2.   

Abstract

The National Institutes of Health global score for chronic graft-versus-host disease was devised by experts but was not based on empirical data. We hypothesized that analysis of prospectively collected data would enable derivation of a more accurate model for estimating mortality risk. We analyzed 574 adult patients with chronic graft-versus-host disease enrolled in a multicenter, observational study, using multivariate time-varying analysis accounting for serial changes in severity of involvement of eight individual organ sites over time. In the training set, severity of skin, mouth, gastrointestinal tract, liver and lung involvement were independently associated with the risk of non-relapse mortality. Weighted mortality points were assigned to individual organs based on the hazard ratios and were summed. The population was divided into three risk groups based on the total mortality points. The three new risk groups were validated in an independent validation set, but did not show better discriminative performance than the National Institutes of Health global score. As compared to a moderate or mild global score, a severe global score was associated with increased risks of non-relapse and overall mortality across time but not with a decreased risk of recurrent malignancy. The National Institutes of Health global score predicts patients' mortality risk throughout the course of their chronic graft-versus-host disease. Further research is required in order to improve outcomes in patients with severe chronic graft-versus-host disease, since their risk of mortality remains elevated. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2014        PMID: 24997150      PMCID: PMC4181259          DOI: 10.3324/haematol.2014.109611

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.

Authors:  P L Weiden; K M Sullivan; N Flournoy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

2.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

3.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

4.  Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course.

Authors:  J G Clark; S W Crawford; D K Madtes; K M Sullivan
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

5.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

8.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.

Authors:  Joseph Pidala; Xiaoyu Chai; Brenda F Kurland; Yoshihiro Inamoto; Mary E D Flowers; Jeanne Palmer; Nandita Khera; Madan Jagasia; Corey Cutler; Mukta Arora; Georgia Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-06       Impact factor: 5.742

Review 10.  Graft-versus-leukemia reactions in allogeneic chimeras.

Authors:  Hans-Jochem Kolb; Christoph Schmid; A John Barrett; Dolores J Schendel
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

View more
  14 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.

Authors:  Yoshihiro Inamoto; Jennifer White; Reiko Ito; Paul J Martin; Giancarlo Fatobene; Ayumu Ito; Takashi Tanaka; Saiko Kurosawa; Sung-Won Kim; Merav Bar; Mohamed L Sorror; Brenda M Sandmaier; Stephanie J Lee; Takahiro Fukuda; Mary E D Flowers
Journal:  Blood Adv       Date:  2019-09-24

3.  Disease severity in chronic graft-versus-host disease: doctors' gut feeling versus biostatistics?

Authors:  Gerard Socié
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

Review 4.  Evolving concepts in prognostic scoring of chronic GvHD.

Authors:  A Lazaryan; M Arora
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.483

5.  Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT.

Authors:  Yu Akahoshi; Hideki Nakasone; Koji Kawamura; Machiko Kusuda; Shunto Kawamura; Junko Takeshita; Nozomu Yoshino; Yukiko Misaki; Kazuki Yoshimura; Ayumi Gomyo; Aki Tanihara; Masaharu Tamaki; Shun-Ichi Kimura; Shinichi Kako; Yoshinobu Kanda
Journal:  Blood Adv       Date:  2019-11-12

Review 6.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

Authors:  Paul J Martin; Stephanie J Lee; Donna Przepiorka; Mary M Horowitz; John Koreth; Georgia B Vogelsang; Irwin Walker; Paul A Carpenter; Linda M Griffith; Gorgun Akpek; Mohamad Mohty; Daniel Wolff; Steven Z Pavletic; Corey S Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-15       Impact factor: 5.742

Review 7.  Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.

Authors:  Alan Bidgoli; Brittany Paige DePriest; Maedeh Vakili Saatloo; Hua Jiang; Denggang Fu; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2022-07-11

Review 8.  Classification systems for chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

9.  Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.

Authors:  Sherrie J Divito; Anders T Aasebø; Tiago R Matos; Pei-Chen Hsieh; Matthew Collin; Christopher P Elco; John T O'Malley; Espen S Bækkevold; Henrik Reims; Tobias Gedde-Dahl; Michael Hagerstrom; Jude Hilaire; John W Lian; Edgar L Milford; Geraldine S Pinkus; Vincent T Ho; Robert J Soiffer; Haesook T Kim; Martin C Mihm; Jerome Ritz; Indira Guleria; Corey S Cutler; Rachael A Clark; Frode L Jahnsen; Thomas S Kupper
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

10.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.